A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Clinical trial NCT07545122 · RECRUITING

Trial details

NCT number: NCT07545122
Sponsor: Context Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC)Colorectal Cancer Urothelial Cancer

Start date: 2026-09-01
Primary completion: 2030-01-01
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.